ACTRN12605000536662
Active, not recruiting
Phase 2
Phase II study to assess the safety and efficacy of allogeneic transplantation using transplant-lite conditioning regimes (Fludarabine and Melphalan) in patients with a diagnosis of a haematological malignancy or metastatic renal cancer who are considered unsuitable for a standard conditioning regime due to age, poor physical status or previous exposure to high dose chemotherapy/radiotherapy.
Dr James Morton0 sites80 target enrollmentSeptember 28, 2005
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Metastatic renal cancer
- Sponsor
- Dr James Morton
- Enrollment
- 80
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Summary of Patient/Donor Eligibility Criteria:1\. Diagnosis of haematological malignancy or metastatic renal cancer. 2\. ECOG performance status 0\-2\. 3\. Either a suitable HLA\-identical sibling donor, fit for peripheral blood stem cell collection (cohort 1\) or a suitable HLA\-mismatched (single HLA mismatch) sibling donor, fit for peripheral blood stem cell collection, available HLA\-identical (HLA\-A,B,DRB1\) unrelated donor or available HLA\-mismatched (single HLA mismatch) unrelated donor (cohort 2\).
Exclusion Criteria
- •No exclusion criteria
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A phase II study to evaluate efficacy and safety of Bevacizumab combined with Cisplatin and S-1 for Advanced Non-Squamous Non-Small-Cell Lung Cancernon-squamous non-small-cell lung cancerJPRN-UMIN000009476The Tokyo cooperative oncology group39
Recruiting
Phase 2
Trifluridine/tipiracil (FTD/TPI) plus ramucirumab (Ram) for advanced gastric cancergastric cancerGastric cancerJPRN-jRCTs041210105Kodera Yasuhiro32
Completed
Phase 2
Phase II study investigating efficacy and safety of TFTD plus bevacizumab by RAS mutation status in patients with unresectable advanced or recurrent colorectal cancer refractory or intolerant to standard chemotherapyJPRN-UMIN000030077Japanese Foundation for Multidisciplinary Treatment of Cancer102
Active, not recruiting
Not Applicable
Safety and efficacy of combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with metastatic melanomaStage IV MelanomaMedDRA version: 14.0Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2010-019033-98-DEniversity Clinical Center of Tuebingen
Completed
Phase 2
Phase II study assessing the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)JPRN-UMIN000020773Translational Research Informatics Center, Foundation for Biomedical Research and Innovation39